SAINT-LAURENT, QC, June 16, 2016 /CNW Telbec/ - Shire Pharma Canada ULC ("Shire") today announced its first collaboration with the Grand Défi Pierre Lavoie. This strategic partnership is a natural association for the two organizations who, through their respective missions, both work towards a healthier world.
The Grand Défi Pierre Lavoie as well as its Foundation support health initiatives in two tangible ways: by creating projects promoting healthy life habits amongst young people and by investing in orphan disease research.
As for Shire, the biotechnology company is focused on serving people affected by rare diseases and other highly specialized conditions.
Sponsor and participant
This year, Shire is sponsoring the webcast of The 1,000 km event which brings together 1,065 cyclists, 450 volunteers and 215 drivers. Shire foresees this as being the first step of what they hope will be a greater collaboration with the Grand Défi Pierre Lavoie team in the future.
Shire will also participate in the Grand Défi 1,000 km event which takes place from this coming June 16th to the 19th. Five employees, the "Rare" Team, will race while proudly bearing the colours of Shire.
"Shire is very proud of this new partnership with the Grand Défi Pierre Lavoie. Our teams have a lot in common, like our shared desire to help people live better lives through the promotion of healthy life habits as well as investing in research for orphan diseases," mentions Eric Tse, General Manager of Shire in Canada.
About The 1,000 km event
- An event whose profits allowed the redistribution of close to 3 million dollars in 2015 to support research and the elementary school sponsorship program.
- A 60-hour cycling course that goes across 83 municipalities, from the Saguenay-Lac-Saint-Jean region to Montréal.
To watch the live coverage of the Grand Défi: http://livestream.com/GDPL
To watch the live coverage of The 1,000 km event, brought to you by Shire: https://livestream.com/GDPL/LE1000KM
To learn more about The 1,000 km event's route: https://www.legdpl.com/le-1000-km/le-1000-km-en-detail/le-parcours-2016
Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, undiagnosed and life-threatening.
Our 22,000 employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.
Working together, the possibilities for our patients, healthcare partners and employees are unprecedented, with significant growth potential for our shareholders.
About Shire Pharma Canada ULC
Shire Pharma Canada ULC is a Shire subsidiary, with offices located in Saint-Laurent (Québec) and Mississauga (Ontario). For more information, please visit www.shirecanada.com.
SOURCE Shire Pharma Canada ULC
For further information: Brigitte Viel, email@example.com, 514 787-5114